Hutch News

How we measure success matters when evaluating HIV therapies

How we measure success matters when evaluating HIV therapies

From Dr. Dan Reeves, Vaccine and Infectious Disease Division
Science SpotlightSeptember 18, 2023
Researchers identify strong T-cell response in first-in-human nanoparticle HIV vaccine

Researchers identify strong T-cell response in first-in-human nanoparticle HIV vaccine

Study result moves scientists closer to developing elusive HIV vaccine
News ReleasesMay 24, 2023
Optimizing antigen design may improve HIV vaccine efforts

Optimizing antigen design may improve HIV vaccine efforts

From the Pancera, McElrath and Stamatatos labs, Vaccine and Infectious Disease and Clinical Research Divisions
Science SpotlightJune 20, 2022
How do antibodies evolve to kill HIV-infected cells?

How do antibodies evolve to kill HIV-infected cells?

From the Overbaugh and Matsen labs, Human Biology and Public Health Sciences Division
Science SpotlightFebruary 15, 2021
All immunogens are not created equal

All immunogens are not created equal

From the Stamatatos lab, Vaccine and Infectious Disease Division
Science SpotlightNovember 16, 2020
Benefits outweigh the social stigma of HIV vaccine trial participation

Benefits outweigh the social stigma of HIV vaccine trial participation

From the HIV Vaccine Trials Network and the University of Washington
Science SpotlightJuly 20, 2020